Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rutgers

Showing results (961-970 of 982) with videos related to

Pageof 99
Sort By:
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
Journal of Personalized Medicine|July 29, 2023
Precision Medicine for More Oxygen (P4O2)-Study Design and First Results of the Long COVID-19 ExtensionNadia Baalbaki, Jelle M Blankestijn, Mahmoud I Abdel-Aziz, et al.
JAMA|July 6, 2021
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis, Manu Shankar-Hari, Claire L Vale, et al.
The Journal of Dermatology|February 14, 2025
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudyNicoline F van Buchem-Post, Wouter Ouwerkerk, Eileen W Stalman, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Journal of Allergy and Clinical Immunology|May 19, 2024
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapyEileen W Stalman, Luuk Wieske, Jim B D Keijser, et al.
Breast (Edinburgh, Scotland)|April 2, 2022
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapyWalter Paul Weber, Jane Shaw, Andrea Pusic, et al.
The Lancet. Rheumatology|May 9, 2022
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studiesLaura Boekel, Eileen W Stalman, Luuk Wieske, et al.
International Journal of Cancer|September 18, 2014
Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factorsAnja Rudolph, Roger L Milne, Thérèse Truong, et al.
Pageof 99

Showing results (961-970 of 982) with videos related to

Sort By:
Pageof 99
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
Journal of Personalized Medicine|July 29, 2023
Precision Medicine for More Oxygen (P4O2)-Study Design and First Results of the Long COVID-19 ExtensionNadia Baalbaki, Jelle M Blankestijn, Mahmoud I Abdel-Aziz, et al.
JAMA|July 6, 2021
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis, Manu Shankar-Hari, Claire L Vale, et al.
The Journal of Dermatology|February 14, 2025
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudyNicoline F van Buchem-Post, Wouter Ouwerkerk, Eileen W Stalman, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Journal of Allergy and Clinical Immunology|May 19, 2024
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapyEileen W Stalman, Luuk Wieske, Jim B D Keijser, et al.
Breast (Edinburgh, Scotland)|April 2, 2022
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapyWalter Paul Weber, Jane Shaw, Andrea Pusic, et al.
The Lancet. Rheumatology|May 9, 2022
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studiesLaura Boekel, Eileen W Stalman, Luuk Wieske, et al.
International Journal of Cancer|September 18, 2014
Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factorsAnja Rudolph, Roger L Milne, Thérèse Truong, et al.
Pageof 99